A Phase 1, Randomized, Participant-and Investigator-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose, Drug-Drug Interaction and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3509754 in Healthy Non-Japanese and Japanese Participants
Latest Information Update: 23 Dec 2022
At a glance
- Drugs LY 3509754 (Primary) ; Itraconazole; Midazolam
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 19 Dec 2022 Status changed from suspended to discontinued.
- 12 Sep 2022 Planned End Date changed from 28 Feb 2022 to 30 Sep 2022.
- 12 Sep 2022 Planned primary completion date changed from 28 Feb 2022 to 30 Sep 2022.